The heterozygous germ line mutation 1100delC of CHK2 was previously reported to be associated to breast cancer [18], bladder cancer [23] and prostate cancer [19-22] and perhaps also to other carcinomas [20,24,25]. Here, CHEK2 is linked to prostate cancer.